Modality
mAb
MOA
PLK4i
Target
FcRn
Pathway
Complement
ALLHeart Failure
Development Pipeline
Preclinical
Jan 2020
→ Mar 2029
PreclinicalCurrent
NCT07533432
40 pts·Heart Failure
2024-11→2029-03·Terminated
NCT07209254
948 pts·Heart Failure
2020-01→2026-11·Terminated
988 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-11-228mo awayInterim· Heart Failure
2029-03-122.9y awayInterim· Heart Failure
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
Preclinical
Termina…
Preclinical
Termina…
Catalysts
Interim
2026-11-22 · 8mo away
Heart Failure
Interim
2029-03-12 · 2.9y away
Heart Failure
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07533432 | Preclinical | Heart Failure | Terminated | 40 | Biomarker |
| NCT07209254 | Preclinical | Heart Failure | Terminated | 948 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| ITC-879 | Intra-Cellular | Approved | FcRn | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| Liravorutinib | Biomea Fusion | Phase 1/2 | GPRC5D | |
| GLP-5658 | Galapagos | Phase 2/3 | FcRn |